Literature DB >> 7931184

Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology.

A Andersson1, V Vetter, L Kreutzer, G Bauer.   

Abstract

Classical Epstein-Barr virus (EBV) serology can be misleading in some cases due to the variability of the viral capsid antigen (VCA)-IgM response, persistent or reactivated VCA-IgM, or loss of anti-EBNA-1 during suppression of the cellular immune system. Therefore, we studied the usefulness and significance of avidity determinations of VCA-IgG and EA-IgG to achieve unequivocal interpretation of serological results. Avidities of EBV capsid antigen-specific IgG (VCA-IgG) and early antigen-specific IgG (EA-IgG) were determined by indirect immunofluorescence during and after acute EBV infection. Low-avidity antibodies were removed from antigen-antibody complexes by incubation with 6 M urea for 3 minutes. The analysis of 105 sera taken at defined time spans with regard to the onset of clinical symptoms allowed us to determine the kinetics of maturation of avidity of VCA-IgG. All sera had low-avidity antibodies at the onset of disease. More than 90% of the sera showed an avidity index below 0.25 during the first 10 days after the onset of disease. Fifty percent of the sera exhibited an avidity index of 0.25 or above 20-30 days after the onset of clinical symptoms. Sera from past infections uniformly exhibited avidity indices of 0.5 or 1. Avidity of EA-IgG may still be low when avidity of VCA-IgG is already borderline or high, thus allowing further differentiation of acute and recent infections. Avidity determination represents an important additional marker of serology in classical cases and allows diagnosis in aberrant cases, such as acute infections with low or undetectable VCA-IgM.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931184     DOI: 10.1002/jmv.1890430308

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

1.  A new method with general diagnostic utility for the calculation of immunoglobulin G avidity.

Authors:  M H Korhonen; J Brunstein; H Haario; A Katnikov; R Rescaldani; K Hedman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years.

Authors:  Ralf D Hess
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia.

Authors:  Faith Dickerson; Emily Katsafanas; Andrea Origoni; Amalia Squire; Sunil Khushalani; Theresa Newman; Kelly Rowe; Cassie Stallings; Christina L G Savage; Kevin Sweeney; Tanya T Nguyen; Alan Breier; Donald Goff; Glen Ford; Lorraine Jones-Brando; Robert Yolken
Journal:  Schizophr Res       Date:  2021-01-12       Impact factor: 4.939

Review 4.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

5.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

7.  Atypical immune response to Epstein-Barr virus in major depressive disorder.

Authors:  Lorraine Jones-Brando; Faith Dickerson; Glen Ford; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Kevin Sweeney; Amalia Squire; Sunil Khushalani; Robert Yolken
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

8.  Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.

Authors:  Pengcheng Wang; Xinzhen Yang
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

9.  Antibody maturation in Trypanosoma cruzi-infected rats.

Authors:  I S Marcipar; M G Risso; A M Silber; S Revelli; A J Marcipar
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

Review 10.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.